

**Saturday,
September 9, 2017**
Bilbao Auditorium Hall 4
IFEMA
Feria de Madrid
Madrid, Spain
13.00-14.30

Faculty



Dirk Arnold

Clinic and Polyclinic for
Internal Medicine IV,
Universitätsklinikum Halle,
Halle, Germany, now with
CUF Hospitals Cancer Centre,
Lisboa, Portugal



Alfredo Carrato

Department of Medical
Oncology, Ramon y Cajal
University Hospital, Ramon
y Cajal Institute for Health
Research - IRYCIS, Alcala
University, CIBERONC,
Madrid, Spain



Sylvie Dolbeault

Institut Curie, Supportive Care
Department, Psycho-oncology
Unit, Paris, France
CESP, University Paris-Sud,
UVSQ, INSERM, University
Paris-Saclay,
Villejuif, France



Alfredo Falcone

Department of Oncology,
Azienda Ospedaliero-
Universitaria Pisana and
University of Pisa, Istituto
Toscano Tumori, Santa Chiara
Hospital,
Pisa, Italy



Alexander Stein

Department of Oncology
and Hematology, BMT with
section Pneumology, Hubertus
Wald Tumorzentrum/UCCH,
University Medical Center
Hamburg-Eppendorf,
Hamburg, Germany



Harpreet Wasan

Department of Oncology,
Imperial College Healthcare
NHS Trust, Hammersmith
Hospital,
London, UK

ESMO 2017 Industry Satellite Symposium

Scientific programme

Therapeutic options for the patient beyond 2nd line in mCRC

Chairpersons:

A. Falcone (Italy)

A. Carrato (Spain)

Introduction

A. Carrato (Spain)

Optimal treatment sequencing in mCRC

D. Arnold (Portugal)

The clinical value of treatment beyond 2nd line for the patient

A. Stein (Germany)

The importance of patient involvement in treatment decisions

- Perspective of an onco-psychiatrist

S. Dolbeault (France)

- Perspective of a medical oncologist

H. Wasan (UK)

Discussion and meeting close

A. Falcone (Italy)

Organized by

